Quick Answer
AbCellera Biologics Inc. reported Revenue (ASC 606) of $75.13 million for fiscal year 2025.
AbCellera Biologics Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $75.13M | +160.6% |
| 2024 | $28.83M | -24.2% |
| 2023 | $38.02M | -92.2% |
| 2022 | $485.42M | +29.4% |
| 2021 | $375.20M | +60.9% |
| 2020 | $233.16M | +1907.9% |
| 2019 | $11.61M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.96M | +37.6% | -47.6% |
| June 30, 2025 | $17.08M | +133.3% | +303.4% |
| March 31, 2025 | $4.24M | -57.5% | -34.9% |
| September 30, 2024 | $6.51M | -1.4% | -11.1% |
| June 30, 2024 | $7.32M | -27.2% | -26.4% |
| March 31, 2024 | $9.95M | -18.4% | +50.8% |
| September 30, 2023 | $6.60M | -93.5% | -34.4% |
| June 30, 2023 | $10.06M | -78.1% | -17.5% |
- AbCellera Biologics Inc. showed an increase of +160.6% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2019–2025 period, AbCellera Biologics Inc.’s revenue (asc 606) has grown by 547.0% (from $11.61 million to $75.13 million).
- The most recent figure is from AbCellera Biologics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: